Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysis

D. Price, R. Jones, K. Gruffydd-Jones, G. Brusselle, M. Miravitlles, M. Baldwin, R. Stewart, D. L. Keininger (Aberdeen, Plymouth, Wiltshire, Horsham, West Sussex, Cambridge, United Kingdom; Ghent, Belgium; Barcelona, Spain; Basel, Switzerland)

Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Session: New clinical evidence for asthma and COPD treatments
Session type: Thematic Poster Session
Number: 2411
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Price, R. Jones, K. Gruffydd-Jones, G. Brusselle, M. Miravitlles, M. Baldwin, R. Stewart, D. L. Keininger (Aberdeen, Plymouth, Wiltshire, Horsham, West Sussex, Cambridge, United Kingdom; Ghent, Belgium; Barcelona, Spain; Basel, Switzerland). Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysis. Eur Respir J 2014; 44: Suppl. 58, 2411

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014

Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Distribution and outcomes of the new Spanish phenotype-based guideline for COPD
Source: International Congress 2014 – COPD exacerbations
Year: 2014

Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Validation of a new inhaled therapeutic algorithm for the stable COPD patient: The COPD easy treatment project
Source: International Congress 2015 – Management of COPD and other respiratory diseases in primary care
Year: 2015


What are common COPD symptoms in a real-life setting? The German DACCORD registry
Source: International Congress 2014 – COPD markers
Year: 2014

Combination therapy versus separate therapy in real-life primary care asthma patients
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015


Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015


Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD?
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Effectiveness of a comprehensive management program of fragile COPD patients
Source: International Congress 2014 – Phenotyping and monitoring asthma and COPD
Year: 2014